InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Acquires Ignite Proteomics to Expand Precision Oncology Platform
March 13, 2026
Aditxt (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, announced the acquisition of Ignite Proteomics LLC, a commercial-stage precision oncology company focused on improving therapy selection in cancer care through functional proteomics. Ignite’s Reverse Phase Protein Array platform is designed to measure protein expression and activity directly from tumor samples, providing insight into whether targeted therapies are likely to be effective, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective March 9, 2026
March 5, 2026
Aditxt (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, announced it will implement a 1-for-8 reverse stock split of its common stock effective at the opening of trading on March 9, 2026, while continuing to trade on the Nasdaq Capital Market under the symbol ADTX. The reverse split, approved by stockholders at a […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Outlines bitXbio Strategy and Proposes Corporate Name Change
November 18, 2025
Aditxt (NASDAQ: ADTX), a social innovation platform accelerating health-focused technologies, detailed its bitXbio strategy, a framework connecting public markets, blockchain and Web3, and digital asset treasuries to support breakthrough health innovations through a participation-driven model. The Company filed a Preliminary Proxy Statement seeking shareholder approval for several proposals, including an Employee Stock Purchase Plan and […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective Nov. 3, 2025
October 30, 2025
Aditxt (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, will implement a 1-for-113 reverse stock split of its common stock effective at the opening of trading on Nov. 3, 2025. The stock will continue trading under the symbol ADTX. Following the split, every 113 shares of issued and outstanding common stock will convert […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Begins Enrollment in Clinical Study for Blood-Based Endometriosis Test
October 27, 2025
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health innovations, announced that its subsidiary Pearsanta Inc. has initiated enrollment in a prospective clinical study evaluating the Mitomic (R) Endometriosis Test (MET(TM)), a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET’s performance to laparoscopic diagnosis, the current gold standard, across up […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Portfolio Company CEO Honored at 2025 STIMULATE Conference
August 5, 2025
Aditxt (NASDAQ: ADTX), announced that Saundra Pelletier, CEO of Evofem Biosciences—its pending acquisition target—has received the Trailblazing Female Founders Award at the 2025 STIMULATE Conference in Nashville. Recognized for advancing women’s sexual and reproductive health, Pelletier leads Evofem, the developer of hormone-free contraceptive PHEXXI(R) and SOLOSEC(R), an oral treatment for bacterial vaginosis and trichomoniasis. The […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Engages Spartan Capital as Lead Underwriter for Planned IPO
July 29, 2025
Aditxt (NASDAQ: ADTX), a social innovation platform focused on accelerating health innovations, announced that its subsidiary Pearsanta, Inc. has engaged Spartan Capital Securities, LLC as lead underwriter for its planned Initial Public Offering. The proposed IPO is intended to support the clinical validation and commercial rollout of Pearsanta’s early cancer and disease detection tests powered […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Invited to Submit Full Proposal for DoD-Funded Ovarian Cancer Diagnostic Study
July 24, 2025
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health technologies, announced that its subsidiary Pearsanta, Inc. has been invited to submit a full proposal for the U.S. Department of Defense’s OCRP Pilot Award. The proposal supports Pearsanta’s Mitomic(R) Ovarian Test (MOT(TM)), a novel blood-based diagnostic aimed at early ovarian cancer detection. Pearsanta’s pre-proposal was favorably […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host July 22 Livestream on Autoimmune Therapeutics Subsidiary Adimune
July 22, 2025
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health solutions, will host a livestream on July 22, 2025, at 1:00 p.m. ET to highlight its autoimmune therapeutics subsidiary, Adimune Inc. The event, hosted by Jack Marks of Wall Street Reporter, will feature Aditxt Co-founder and CEO Amro Albanna discussing Adimune’s innovative approach, upcoming milestones, and […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) CEO to Present at Wall Street Reporter’s NEXT SUPER STOCK Event June 26
June 26, 2025
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health breakthroughs, announced that Co-founder and CEO Amro Albanna will present at the NEXT SUPER STOCK livestream hosted by Wall Street Reporter on June 26, 2025, at 1:00 p.m. ET. Albanna will outline Aditxt’s innovation acceleration model, provide updates on its autoimmunity and early cancer detection programs, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
June 9, 2025
Aditxt (NASDAQ: ADTX) has appointed Saundra Pelletier, CEO of Evofem Biosciences (OTCPK: EVFM), to its Board of Directors as the company advances toward commercialization and sharpens its focus on women’s health. Pelletier brings more than 30 years of global pharmaceutical experience, including launching and expanding brands across women’s reproductive health. At Evofem, she led the […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Terminates Acquisition Agreement with Appili Therapeutics
May 19, 2025
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health innovations, announced its decision to terminate the Arrangement Agreement with Appili Therapeutics Inc., effective May 31, 2025. The agreement, first announced in April 2024, had been amended multiple times to address evolving conditions. Aditxt cited a lack of strategic alignment as the reason for discontinuing the […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights ADI-100 Developments in Weekly Update Featuring Leadership Team
May 2, 2025
Aditxt (NASDAQ: ADTX) announced that Chief Innovation Officer Dr. Shahrokh Shabahang and Adimune Co-CEO Dr. Friedrich Kapp will participate in today’s Aditxt Weekly Update to discuss recent progress on ADI-100™, the lead therapeutic candidate of its wholly owned subsidiary, Adimune. The company continues to spotlight advancements within its health innovation portfolio as it accelerates development […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Mayo Clinic’s Dr. Charles Howe in May 2 Update on ADI-100™ Preclinical Study
April 17, 2025
Aditxt (NASDAQ: ADTX) announced that Dr. Charles Howe of the Mayo Clinic will join the Company’s Weekly Update on May 2, 2025, to discuss key findings from a newly announced preclinical study of ADI-100™, the lead therapeutic candidate from Aditxt’s subsidiary, Adimune Inc. The update will also feature Dr. Shahrokh Shabahang, Aditxt’s Chief Innovation Officer, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Gains IRB Approval for Endometriosis Diagnostic Study
April 16, 2025
Aditxt (NASDAQ: ADTX) announced that its subsidiary Pearsanta has received Institutional Review Board approval to initiate a clinical study evaluating the Mitomic Endometriosis Test (MET), a blood-based diagnostic aimed at early detection of endometriosis. The study will enroll up to 1,000 participants beginning in May 2025 and compare MET results to laparoscopic diagnoses, the current […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Advances Autoimmune Therapy Following Positive Mayo Clinic Study on ADI-100
April 14, 2025
Aditxt (NASDAQ: ADTX) announced that a Mayo Clinic-led study has validated preclinical findings for ADI-100, the lead autoimmune therapy candidate developed by its subsidiary Adimune Inc. The study confirmed ADI-100’s ability to induce immune tolerance to glutamic acid decarboxylase (GAD), a key trigger in several autoimmune conditions including type 1 diabetes and stiff person syndrome. […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance and Previews Strategic Updates
April 11, 2025
Aditxt (NASDAQ: ADTX) a social innovation platform focused on advancing health innovations, announced that its latest Aditxt Weekly Update will highlight several key developments. The Company recently received a notice from Nasdaq confirming it has regained compliance with the minimum bid price requirement, ensuring continued listing on the Nasdaq Capital Market. The update will also […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance, Hearing Canceled
April 9, 2025
Aditxt (NASDAQ: ADTX) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2), eliminating the need for a previously scheduled hearing with the exchange’s Hearings Panel. The company’s stock will continue trading on the Nasdaq Capital Market under the ticker ADTX as it advances health innovation efforts targeting autoimmunity, cancer, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Appili CEO in April 4 Update Focused on Infectious Disease Innovation
April 2, 2025
Aditxt (NASDAQ: ADTX), a social innovation platform accelerating health breakthroughs, announced that Don Cilla, Pharm.D., M.B.A., CEO of Appili Therapeutics, will join its Weekly Update on April 4 at 11:30 a.m. ET. The session will spotlight the growing need for infectious disease treatments and explore how partnerships like Aditxt and Appili’s can fast-track health innovations. […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights CaSe Platform Acquisition in Weekly Update Focused on Early Cancer Detection
March 28, 2025
Aditxt (NASDAQ: ADTX), a social innovation platform focused on accelerating health technologies, announced that its latest Aditxt Weekly Update will spotlight the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. The proprietary technology, based on adductomics, is engineered to detect early DNA changes that could lead to cancer and other diseases. The […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Acquires Patents for DNA Damage Detection in Cancer Prevention
March 24, 2025
Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, Inc., has acquired key patents for adductomics-based DNA damage detection in a $1 million stock transaction. The move expands Pearsanta’s capabilities in early cancer risk assessment, complementing its existing Mitomic® Technology. The acquired technology detects DNA adducts—early markers of carcinogen exposure—allowing for potential cancer prevention strategies before […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Provides Update on Appili Therapeutics Acquisition and Federal Funding Applications
March 18, 2025
Aditxt (NASDAQ: ADTX) through its wholly owned subsidiary Adivir, Inc., is progressing with its planned acquisition of Appili Therapeutics (TSX: APLI; OTCPink: APLIF) under a court-approved plan of arrangement. Appili shareholders have overwhelmingly approved the transaction, and the company has secured all necessary court approvals. The closing remains contingent on Aditxt securing sufficient financing, with […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Provides Corporate Update, Announces Weekly Investor Series
March 17, 2025
Aditxt (NASDAQ: ADTX), a health innovation platform, provided a corporate update highlighting progress across its subsidiaries and acquisition initiatives. The company remains focused on advancing its autoimmune treatment subsidiary Adimune™, precision diagnostics unit Pearsanta™, and neurological monitoring subsidiary Adivue™, while also pursuing strategic acquisitions, including Appili Therapeutics and Evofem Biosciences. Additionally, Aditxt will launch its […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Advances ADI-100 Autoimmune Therapy Toward Clinical Trials
March 6, 2025
Aditxt (NASDAQ: ADTX) provided an update on its subsidiary, Adimune, Inc., and the progress of ADI-100, an investigational gene therapy targeting autoimmune diseases such as psoriasis, Type 1 diabetes, and Stiff Person Syndrome. Adimune has completed preclinical studies and is preparing for drug substance shipment in March, with clinical trials planned in Germany and an […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Engages Lead Underwriter for Planned IPO
February 21, 2025
Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, has engaged Dominari Securities LLC as the lead underwriter for its planned initial public offering (IPO), expected in the second half of 2025. The IPO aims to support Pearsanta’s commercialization of its Mitomic® Technology platform for early cancer detection, leveraging mitochondrial DNA biomarkers for non-invasive diagnostics. Funds […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Fireside Chat on Feb. 21 to Discuss Key Corporate Developments
February 13, 2025
Aditxt (NASDAQ: ADTX), a social innovation platform focused on advancing health innovations, will host a virtual Fireside Chat on Feb. 21, 2025, at 11:30 a.m. ET. CEO Amro Albanna will provide updates on the company’s subsidiaries, potential transactions, and pipeline advancements. The discussion will highlight Adimune, Inc.’s progress in autoimmunity treatments, including Type 1 Diabetes […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Explores IPO for Pearsanta to Advance Early Cancer Detection
January 13, 2025
Aditxt (NASDAQ: ADTX) a social innovation platform dedicated to advancing health innovations, announced its Board of Directors has authorized management to explore an initial public offering (“IPO”) for its subsidiary, Pearsanta, Inc., in 2025. Pearsanta, a precision diagnostics company leveraging its proprietary Mitomic® Technology platform for early cancer detection, aims to use the IPO proceeds […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Advances ADI-100 Gene Therapy Toward Human Trials
December 12, 2024
Aditxt (NASDAQ: ADTX) announced that its subsidiary, Adimune, Inc., has completed all preclinical efficacy and safety studies for ADI-100, an innovative antigen-specific gene therapy for autoimmune diseases such as Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome. Preclinical results demonstrated ADI-100’s ability to restore immune tolerance without impairing the immune system’s infection or tumor-fighting capabilities, showing […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Updates Shareholders on Equity Issuance and Shift to Debt Financing Strategy
November 8, 2024
Aditxt (NASDAQ: ADTX) provided shareholders with an update on its capital structure, disclosing details on shares issued through its Equity Line of Credit (“ELOC”) and At-the-Market (“ATM”) facility since activation. As of Nov. 7, 2024, Aditxt has sold approximately 11.9 million shares, representing 8% of the total 153 million shares traded since the ELOC and […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Acquisition of Appili Therapeutics Moves Forward with Overwhelming Shareholder Approval
November 7, 2024
Aditxt (NASDAQ: ADTX) announced a significant advancement in its acquisition of Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF), as Appili shareholders voted overwhelmingly in favor of the proposed plan for Aditxt to acquire all Class A common shares of Appili. This positive shareholder response marks a key step in Aditxt’s strategy to expand its health […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Gains Support for Evofem Merger as Voting Agreements Secure Favorable Votes
November 6, 2024
Aditxt (NASDAQ: ADTX) announced today that its acquisition target, Evofem Biosciences, Inc. (OTCQB: EVFM), has secured voting agreements from key investors, solidifying their commitment to vote in favor of the upcoming merger proposal at Evofem’s Special Meeting of Stockholders. This move advances Aditxt’s planned acquisition to establish a stronghold in women’s health through Evofem. Aditxt’s […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Hold CEO-Led Update and Q&A Session Covering Company Developments
October 31, 2024
Aditxt (NASDAQ: ADTX) will host a live update and Q&A session with CEO Amro Albanna on Friday, Nov. 1, 2024, at 11:30 a.m. ET. The session will offer stakeholders insights into the company’s current initiatives, provide transaction and Nasdaq compliance updates, and include a Q&A segment addressing pre-submitted questions from investors and the public. To […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Strengthens Leadership with Appointment of Governance Expert Sylvia Hermina to Board
October 29, 2024
Aditxt (NASDAQ: ADTX) has appointed Sylvia Hermina to its Board of Directors, adding over 20 years of expertise in corporate governance, M&A, and shareholder relations to its leadership. As a Senior VP at Kingsdale Advisors, Hermina has played a key role in the firm’s U.S. expansion and strategic M&A initiatives. Aditxt CEO Amro Albanna highlighted […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves Closer to Evofem Acquisition with Final Investment Milestone
October 28, 2024
Aditxt (NASDAQ: ADTX) has completed a key milestone toward its acquisition of Evofem Biosciences, Inc. (OTCQB: EVFM) by purchasing $2.28 million in Evofem Series F-1 convertible preferred stock, as stipulated under their Amended and Restated Merger Agreement. This investment represents Aditxt’s final funding commitment before the merger, where Evofem, known for women’s health innovations, would […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Hosts Virtual Fireside Chat to Discuss Evofem Acquisition and Future Strategic Plans
October 21, 2024
Aditxt (NASDAQ: ADTX) announced a virtual fireside chat on Oct. 28, 2024, featuring Aditxt CEO Amro Albanna and Evofem Biosciences CEO Saundra Pelletier, moderated by Dr. Drew Pinsky. The discussion will provide updates on Aditxt’s acquisition of Evofem, post-acquisition strategies, and the companies’ plans to enhance women’s health care solutions. Key topics include Evofem’s FDA-approved […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Acquisition Target Plans Special Meeting of Shareholders to Obtain Transaction Approval
October 10, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, is reporting that Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) has begun mailing its management information circular related to the company’s special meeting of shareholders, which is scheduled for next month. According to the announcement, the meeting will be held virtually on Nov. 6, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Schedules Stakeholder Update, Q&A Session with CEO
October 9, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, today announced that Amro Albanna, Co-Founder, Chairman, and CEO of the company, will host a stakeholder update and Q&A session on Friday, October 11, 2024, at 11:30 a.m. EDT. The session will cover the company’s current position and progress regarding the […]
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX), Evofem Announce Completion of Third Parent Equity Investment Under Amended Merger Agreement
October 8, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and its acquisition target Evofem Biosciences (OTCQB: EVFM), a women’s health company, have completed the Third Parent Equity Investment under its Amended and Restated Merger Agreement. According to the announcement, this strengthens the strategic and collaborative relationship between the two companies, which share a […]
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Releases Shareholder Update, Plans for Remainder of 2024
October 3, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, is reporting to shareholders on plans for the 2024 year end. Highlights of the report include news about its two acquisition targets: Evofem Biosciences (OTCQB: EVFM) has reported $7.8 million in revenue for the first six months of 2024, while Appili Therapeutics Inc. (TSX: […]
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval
September 24, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, has reported that its acquisition target, Evofem Biosciences (OTCQB: EVFM), a women’s health company, has filed a preliminary proxy. The proxy is seeking stockholder approval of transactions outlined under the Amended and Restated Merger Agreement with Aditxt and Adifem Inc., a wholly owned subsidiary of […]